Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentre, Randomized, Open-label Study to Prove an Additional Benefit of the Full-spectrum Cannabis Extract VER-01 Over Opioids in the Treatment of Patients With Chronic Non-specific Low Back Pain

Next Previous
Trial Profile

Multicentre, Randomized, Open-label Study to Prove an Additional Benefit of the Full-spectrum Cannabis Extract VER-01 Over Opioids in the Treatment of Patients With Chronic Non-specific Low Back Pain

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dronabinol (Primary) ; Buprenorphine; Fentanyl; Hydromorphone; Morphine; Naloxone; Oxycodone; Tapentadol; Tilidine; Tramadol
  • Indications Back pain
  • Focus Adverse reactions; Registrational
  • Acronyms ELEVATE
  • Sponsors Vertanical

Most Recent Events

  • 01 Oct 2025 Results presented in Vertanical media release.
  • 01 Oct 2025 According to a Vertanical media release, Based on results of Phase 3 studies, VERTANICAL submitted VER-01 for marketing authorization in multiple European countries for the treatment of chronic low back pain.
  • 01 Oct 2025 Primary endpoint (Risk of developing constipation) has been met, according to a Vertanical media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top